<DOC>
	<DOCNO>NCT00944541</DOCNO>
	<brief_summary>This pilot study aim evaluate Maraviroc intensification strategy 24 week HIV infect patient efficient ( CV &lt; 50 cp/mL ) , control antiretroviral therapy ( â‰¥ 6 month ) uncompleted immune restoration ( CD4 &lt; 350 cells/mL CD4 earn &lt; 100 cells/mL last 24 month ) . The study include 60 patient whose follow carry 48 week . recruitment period maintain 12 month .</brief_summary>
	<brief_title>Evaluation Maraviroc Intensification HIV Infected Patients With Insufficient Immune Restoration</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>HIV1 infection maravirocnaives patient CD4 le 350 cells/mm3 viral load le 50 cp/mL CD4 earn less 100 cells/mm3 last 24 month HIV2 infection X4 tropism inclusion pregnancy breast feed interferon , immunomodulatory drug treatment antiHIV vaccine chemotherapy hypersensibility peanut soya</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>maraviroc</keyword>
	<keyword>immune restoration</keyword>
	<keyword>treatment intensification</keyword>
</DOC>